Although this study breaks important new ground, it will be useful to further verify this effect in the more complex environment found inside cells. A key experiment will be to analyze the effect of inositol phospholipids, such as PIP 2 , on this process given that they regulate both Arp2/3-activating proteins (such as N-WASP) and capping protein. It will also be exciting to see these ideas incorporated into future biophysical models of actin polymerization-induced force generation. The signals delivered by members of the transforming growth factor β (TGF-β) protein family are central to the specification of germ cell identity in embryonic development. In the endoderm, maternal factors activate the expression of TGF-β ligands that in turn induce overlying cells to become mesoderm ( Figure  1 ). Yet, how this induction remains confined to cells lying at the equator of the embryo leaving the ectoderm pluripotent remains unclear (Niehrs, 2004) . Recent embryological and molecular evidence argues that the development of a pluripotent ectoderm appears to result from an active molecular process in which cells constantly keep TGF-β signaling in check. For example, prior to gastrulation, the embryo requires an ectodermspecific maternal determinant, Ectodermin/Tif1γ, that ubiquitinates Smad4, inhibiting its activity (Dupont et al., 2005) . At the end of gastrulation, once germ layers have been induced, TGF-β then takes on other duties. At the gastrula stage, TGF-β ligands signal through Smad2 to start dividing the ectoderm into neural and non-neural territories along the dorsoventral axis (Figure 1 ) (Chang and Harland, 2007) . Paradoxically, this event is not temporally isolated from mesoderm induction (Camus et al., 2006) . It is unclear how embryos seamlessly orchestrate what appear to be diametrically opposing needs: avoiding TGF-β-mediated transformation of the ectoderm into mesoderm while at the same time using TGF-β for ectodermal patterning.
The signals delivered by members of the transforming growth factor β (TGF-β) protein family are central to the specification of germ cell identity in embryonic development. In the endoderm, maternal factors activate the expression of TGF-β ligands that in turn induce overlying cells to become mesoderm ( Figure  1 ). Yet, how this induction remains confined to cells lying at the equator of the embryo leaving the ectoderm pluripotent remains unclear (Niehrs, 2004) . Recent embryological and molecular evidence argues that the development of a pluripotent ectoderm appears to result from an active molecular process in which cells constantly keep TGF-β signaling in check. For example, prior to gastrulation, the embryo requires an ectodermspecific maternal determinant, Ectodermin/Tif1γ, that ubiquitinates Smad4, inhibiting its activity (Dupont et al., 2005) . At the end of gastrulation, once germ layers have been induced, TGF-β then takes on other duties. At the gastrula stage, TGF-β ligands signal through Smad2 to start dividing the ectoderm into neural and non-neural territories along the dorsoventral axis (Figure 1 ) (Chang and Harland, 2007) . Paradoxically, this event is not temporally isolated from mesoderm induction (Camus et al., 2006) . It is unclear how embryos seamlessly orchestrate what appear to be diametrically opposing needs: avoiding TGF-β-mediated transformation of the ectoderm into mesoderm while at the same time using TGF-β for ectodermal patterning.
The work of Sasai et al. (2008) in this issue of Cell provides an elegant solution to this conundrum (Sasai et al., 2008) . They clone, from the frog Xenopus, a new ectoderm-specific gene encoding XFDL156, which has the remarkable capacity to uncouple TGF-β responses from mesodermal differentiation. The real surprise and excitement about this discovery comes from its mechanism of action-XFDL156 is a new antagonist of the p53 tumor suppressor that leaves the TGF-β/Smad pathway operational.
Expression cloning in Xenopus embryos was the route taken to this discovery (Smith and Harland, 1992) . It is remarkable that in the era of shortinterfering RNA (siRNA) libraries and genome-wide mutagenesis screens, this straightforward and purely gain-offunction approach continues to uncover some of the most interesting new genes, suggesting that we are still far from saturation. As in any screen, the experimental strategy is critical. Sasai et al. searched almost 20,000 genes specifically expressed at the end of gastrulation and assayed for those able to inhibit TGF-β induction of mesoderm in explanted ectoderm cells.
p53 Regulation orchestrates the tgf-β Response
Members of the p53 family are integral elements in many TGF-β gene responses. The p53 tumor suppressor binds to Smad2 to form transcriptional cooperating complexes required for the activation of multiple mesodermal genes in Xenopus embryos and for the deployment of the TGF-β cytostatic program in mammalian cells (Cordenonsi et al., 2003) . Unlike the case in mouse embryos, p53 is the only family member expressed at early stages of Xenopus development. This has greatly facilitated the dissection of the p53 pathway in frog embryos microinjected with anti-p53 morpholino oligonucleotides (Cordenonsi et al., 2003) . Sasai et al. (2008) show that overexpression of XFDL156 blocks mesoderm differentiation in whole embryos, phenocopying p53 inactivation. Conversely, loss of XFDL156 recapitulates p53 gain of function, converting embryonic territories that would normally develop as ectoderm into mesoderm. In these assays, p53 mediates the effect of XFDL156 and, notably, neither Smad localization nor activity is involved. Using coimmunoprecipitations and chromatin immunoprecipitation assays, the authors find that XFDL156 binds to p53 and reduces its affinity for target promoters in vivo.
Understanding how cells integrate a handful of signaling pathways to unfurl distinct cellular differentiation programs is a critical challenge in developmental biology and medicine. A case in point is the intersection between fibroblast growth factor (FGF) and TGF-β signals. In embryos, FGFs are required for mesoderm development, acting in concert with TGF-β (Niehrs, 2004) . For these effects, FGF is a positive effector of Smad activity, but remarkably this is attained only through an indirect mechanism: MAPK activity promotes p53 phosphorylation, and this enables a robust p53/Smad interaction in the marginal zone of the embryo (Cordenonsi et al., 2007) . In contrast, within the ectoderm, FGF/MAPK directly inhibits Smads by triggering an inhibitory phosphorylation in the middle region of Smad that promotes neural development (De Robertis, 2006) . These observations could now be reconciled in light of the presence of this new factor restricted to ectoderm, XFDL156. By forestalling any p53 function in ectoderm, XFDL156 expression would confine FGFinduced p53/Smad2 cooperation to the mesoderm while allowing the FGF/Smad inhibitory connection to prevail in the ectoderm.
Thus, an important theme emerging from the Sasai et al. report is that our current model of signaling crosstalk for germ-layer specification needs to be revisited to take into account the temporal and spatial localization of p53 transcriptional activity (Figure 1) . The inhibition of p53 in ectoderm and activation in mesoderm, coupled to gradients of Smad activity along the embryonic poles, provides a simple but remarkably effective means to harmonize the pleiotropic functions of these signaling pathways in pluripotent embryonic cells.
Viewed from another perspective, the cloning of a p53 inhibitory protein that binds to the C terminus of p53 is intriguing, as it helps to shed light on a controversial aspect of p53 regulation. Indeed, the p53 C terminus appears inhibitory for p53 activity in most assays, and relief of this inhibition by acetylation or other events is considered a key activating step for p53 tumor-suppressive functions, yet this domain is also critical for p53 function in other cellular or experimental contexts (Ahn and Prives, 2001) .
Perhaps the solution to these puzzling observations lies in the dynamic and likely dose-or context-specific interactions between p53 and the XFDL protein family. Sasai et al. show that XFDL156 inhibition requires an intact p53 C terminus. XFDL156 does not affect p53 C-terminal acetylation by the p300 acetyltransferase; rather, it is the binding of XFDL156 to p53 that is modulated by p53 C-terminal posttranslational modifications. Indeed, acetylation-mimicking (K to R) or acetylationresistant (K to Q) replacements in the p53 C terminus affect XFDL156 inhibition and lead to coherent changes in p53 activity (up or down, respectively). Further work is required to strengthen these ties and to attain a more mechanistically rich understanding of p53 activation by events that render its C terminus repulsive or attractive for binding to XFDL156. Given that cancer cells contain obligate and persistent p53-activating inputs, the search for the role of XFDL156 in tumors can now begin.
In sum, the Sasai et al. study leaves us with more open questions than answers. Are XFDL-related molecules required for p53 regulation in mammalian cells? Conversely, in addition to p53, do XFDL proteins also target p53 family members p63 and p73? Does XFDL156 target mutant p53 (as expected, given that the C-terminal domain is never mutated in human tumors)? If so, is this truly a candidate oncogene or more like a tumor suppressor? Does this protein family regulate p53 in embryonic stem cells? Is the activity of XFDL156 under the control of additional extracellular cues? Reading the Sasai et al. paper raises the expectation that many intriguing stories are yet to come. TGFβ ligands, primarily Nodal, emanate from the endoderm (yellow) to induce overlying cells to become mesoderm (red). p53, turned on by FGF-mediated phosphorylation, is a required Smad partner in this process. In contrast, the ectoderm (blue) remains pluripotent well-beyond the beginning of gastrulation. This is attained by controlling TGF-β through two temporally distinct mechanisms. Early on, the core TGF-β pathway is downregulated by Smad antagonists, such as ectodermin. Ectodermin/Tif1γ is an ectoderm-specific maternal determinant that ubiquitinates Smad4, inhibiting its activity (Dupont et al., 2005) . In so doing, ectodermin neutralizes both BMP and TGF-β signaling allowing ectoderm development and patterning. Later during gastrulation, the ectoderm expresses XFDL156, an inhibitor of p53 activity (Sasai et al., 2008) . This prevents p53-dependent responses (mesoderm induction) but leaves the core Smad pathway fully operational for distinct effects, namely germ-layer patterning along the dorsoventral (D-V) axis.
